secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001854270-24-000005
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio cuts workforce 37%, extends cash runway to Q1 2025; focuses on SENTI-202
--------------------------------------------------------------------------------

- Workforce reduction of ~37% with one-time severance costs of ~$1M in Q1 2024.
- Cash, equivalents and securities $40.3M as of Nov 30, 2023; runway extended into Q1 2025.
- SENTI-202 Phase 1: first patient dosing expected Q2 2024, initial efficacy data by year-end 2024.
- SENTI-301A with Celest: first patient dosing expected H1 2024.
- Scale back other R&D; continue Spark and BlueRock collaborations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000005/0001854270-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000005/snti-20240103.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer